Cargando…

Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma

BACKGROUND: Non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB-DLBCL) has worse clinical outcome than GCB-DLBCL, and some relapsed/refractory non-GCB-DLBCL (R/R non-GCB-DLBCL) are even resistant to CD20 monoclonal antibody (rituximab). Bruton’s tyrosine kinase inhibitors (BTKis)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Xin, Wei, Ting, Zhong, Weijie, Ang, Rosalind, Lei, Ye, Zhang, Hui, Li, Qingshan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025353/ https://www.ncbi.nlm.nih.gov/pubmed/33827598 http://dx.doi.org/10.1186/s12935-021-01891-2

Ejemplares similares

Identification of BLNK and BTK as mediators of rituximab‐induced programmed cell death by CRISPR screens in GCB‐subtype diffuse large B‐cell lymphoma
por: Thomsen, Emil Aagaard, et al.
Publicado: (2020)

Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
por: Batlle-López, Ana, et al.
Publicado: (2016)

Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma
por: Boltežar, Lučka, et al.
Publicado: (2018)

A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas
por: van der Meeren, L. E., et al.
Publicado: (2019)

BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma
por: Yuan, Hongwei, et al.
Publicado: (2022)

Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis
por: Tsygankova, Svetlana, et al.
Publicado: (2022)

CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain
por: Cho, Junhun, et al.
Publicado: (2022)

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma
por: Ezell, Scott A., et al.
Publicado: (2014)

Identification of a large rearrangement in CYLD as a cause of familial cylindromatosis
por: van den Ouweland, Ans M. W., et al.
Publicado: (2010)

Dynamic changes in peripheral blood lymphocyte subset counts and functions in patients with diffuse large B cell lymphoma during chemotherapy
por: Hou, Hongyan, et al.
Publicado: (2021)

Prognostic impact of platelet-to-lymphocyte ratio on diffuse large B-cell lymphoma: a meta-analysis
por: Chen, Ying, et al.
Publicado: (2019)

Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab
por: Hu, Yunfei, et al.
Publicado: (2014)

SIRT1 rs3758391 polymorphism and risk of diffuse large B cell lymphoma in a Chinese population
por: Kan, Yutian, et al.
Publicado: (2018)

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
por: Zhu, H., et al.
Publicado: (2022)

Cylindromatosis Is Required for Survival of a Subset of Melanoma Cells
por: La, Ting, et al.
Publicado: (2020)

The cylindromatosis (CYLD) gene and head and neck tumorigenesis
por: Verhoeft, Krista Roberta, et al.
Publicado: (2016)

Plastin-3 is a diagnostic and prognostic marker for pancreatic adenocarcinoma and distinguishes from diffuse large B-cell lymphoma
por: Xiong, Fei, et al.
Publicado: (2021)

Down-regulated cylindromatosis enhances NF-κB activation and aggravates inflammation in HBV-ACLF patients
por: Zhang, Xueyun, et al.
Publicado: (2022)

Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma
por: Ma, Jiao, et al.
Publicado: (2015)

Primary Type3 (Non-ABC, Non-GCB) Subtype of Extranodal Diffuse Large B-Cell Lymphoma of the Thyroid Bearing No MYD88 Mutation by Padlock Probe Hybridization
por: Nishi, Yukiko, et al.
Publicado: (2017)

Enrichment of TP53 alterations within GCB-like DNA subclassifications of diffuse large B-cell lymphoma after transition from de-novo to relapsed or refractory disease
por: Lund, Shelby, et al.
Publicado: (2022)

Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment
por: Zheng, Xiaohui, et al.
Publicado: (2014)

Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma
por: Fu, Zhiying, et al.
Publicado: (2014)

Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose–response meta-analysis
por: Mu, Shidai, et al.
Publicado: (2018)

The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms
por: Cai, Ying, et al.
Publicado: (2013)

Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma
por: Ding, Huirong, et al.
Publicado: (2013)

Cylindromatosis mediates neuronal cell death in vitro and in vivo
por: Ganjam, Goutham K., et al.
Publicado: (2018)

Gene selection and cancer type classification of diffuse large-B-cell lymphoma using a bivariate mixture model for two-species data
por: Su, Yuhua, et al.
Publicado: (2013)

Changes of T-lymphocyte subpopulation and differential expression pattern of the T-bet and GATA-3 genes in diffuse large B-cell lymphoma patients after chemotherapy
por: Yin, Qingsong, et al.
Publicado: (2014)

GM-CSF enhanced the effect of CHOP and R-CHOP on inhibiting diffuse large B-cell lymphoma progression via influencing the macrophage polarization
por: Zhang, Yu, et al.
Publicado: (2021)

Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma
por: Nagel, Daniel, et al.
Publicado: (2015)

Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma in vivo and vitro
por: Huang, Shujuan, et al.
Publicado: (2020)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP
por: Li, Jiao, et al.
Publicado: (2017)

The regulation of miR-320a/XBP1 axis through LINC00963 for endoplasmic reticulum stress and autophagy in diffuse large B-cell lymphoma
por: Cui, Yuying, et al.
Publicado: (2021)

Familial Dermal Eccrine Cylindromatosis with Emphasis on Histology and Genetic Mapping
por: Dhir, G, et al.
Publicado: (2013)

The surgical treatment of familial cylindromatosis through subgaleal scalp excision
por: Karalija, Amar, et al.
Publicado: (2015)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

IκB kinase promotes Nrf2 ubiquitination and degradation by phosphorylating cylindromatosis, aggravating oxidative stress injury in obesity-related nephropathy
por: Chen, Yin-Yin, et al.
Publicado: (2021)

Down regulation of G protein-coupled receptor 137 expression inhibits proliferation and promotes apoptosis in leukemia cells
por: Men, Li-Jie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c559crnf4rtekqdb352lm3cojc